Rituximab-induced regression of CREST-related calcinosis
| Autor: | Valderílio Feijó Azevedo, Carolina de Souza Müller, Pedro Gabriel Lorencetti, Dayane Raquel de Paula, Fabiane Barbero Klem |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Pulmonary Fibrosis Arthritis Scleroderma Antibodies Monoclonal Murine-Derived Rheumatology Scleroderma Limited Calcinosis Internal medicine Synovitis Humans Medicine business.industry Remission Induction Lung fibrosis General Medicine Middle Aged medicine.disease Dermatology Antirheumatic Agents Female Crest Rituximab business medicine.drug |
| Zdroj: | Clinical Rheumatology. 32:281-283 |
| ISSN: | 1434-9949 0770-3198 |
| DOI: | 10.1007/s10067-012-2124-z |
| Popis: | About a quarter of sclerodermic patients present calcinosis. However, patients with limited form of the disease are more likely to have calcinosis than patients with diffuse form. We report a case of a 54-year-old female patient with limited cutaneous scleroderma using rituximab (RTX) to treat lung fibrosis and arthritis. Into RTX treatment, she also had a complete resolution of calcinosis in her hands. The patient reported improvement in dyspnea and synovitis after two courses of RTX (four weekly infusions 375 mg/m(2) each). After 7 months of the first infusion, the calcinosis in her fingers had a complete remission, especially the right thumb. Based on current evidences, we discuss the use of rituximab as a promising therapy to treat not only lung disease but also calcinosis in patients with scleroderma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink